Treatment of mice with cytarabine and AZD1775 (formerly MK-1775), a specific WEE1 inhibitor [12], slows the progression of murine AML and prolongs survival more than cytarabine alone [11]. Here, WEE1 is linked to acute myeloid leukemia.